<span item_type="fundamental" item_id="adaa26d27fcebd64da5d442de3b29b01" counter_id="ST/US/JSPRW" env="prod"></span><span item_type="announcement" item_id="581226322976381825" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -1.13.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -19.51 M.</p><p></p><h3>Financial Metrics for Jasper Therapeutics, Inc.</h3><h4>Cash and Cash Equivalents</h4><ul><li>As of September 30, 2025, cash and cash equivalents totaled $50.9 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Research and Development Expenses</h4><ul><li>For the three months ended September 30, 2025, research and development expenses were $14.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>General and Administrative Expenses</h4><ul><li>For the three months ended September 30, 2025, general and administrative expenses were $4.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Jasper reported a net loss of $18.7 million for the three months ended September 30, 2025, with a basic and diluted net loss per share attributable to common stockholders of $1.13.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Total Operating Expenses</h4><ul><li>Total operating expenses for the three months ended September 30, 2025, were $19.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Loss from Operations</h4><ul><li>Loss from operations for the three months ended September 30, 2025, was - $19.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Interest Income</h4><ul><li>Interest income for the three months ended September 30, 2025, was $342,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Change in Fair Value of Warrants Liability</h4><ul><li>The change in fair value of warrants liability for the three months ended September 30, 2025, was $2.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Other Expense, Net</h4><ul><li>Other expense, net for the three months ended September 30, 2025, was - $2.0 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h4>Total Other Income, Net</h4><ul><li>Total other income, net for the three months ended September 30, 2025, was $430,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Jasper plans to report final conclusions from the investigation into the BEACON study’s anomalous efficacy results in the fourth quarter of 2025. They also plan to report initial data from the ETESIAN study in allergic asthma in the fourth quarter and additional data from the BEACON study in the first half of the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea026458601ex99-1_jasper.htm"></span></li></ul>

Jasper Therapeutics - CW26 | 8-K: FY2025 Q3 Revenue: USD 0